- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Earnings Call: Journey Medical meldet Umsatzwachstum für Q3 2025 und stellt positives EBITDA in Aussicht | 5 | Investing.com Deutsch | ||
| 12.11. | Journey Medical GAAP EPS of -$0.09, revenue of $17.6M | 2 | Seeking Alpha | ||
| 12.11. | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 114 | GlobeNewswire (Europe) | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen | |
| 12.11. | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.11. | Insights into Journey Medical's Upcoming Earnings | 13 | Benzinga.com | ||
| 05.11. | Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 | 2 | GlobeNewswire (USA) | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 24.10. | Journey Medical Reports Pooled Phase 3 Data For Emrosi In Rosacea | 2 | RTTNews | ||
| 24.10. | Journey Medical's Emrosi shows superior efficacy for rosacea | 1 | Investing.com | ||
| 26.09. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 22.09. | Summers Value Partners' Update on Journey Medical (DERM) | 5 | Insider Monkey | ||
| 28.08. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 25.08. | H.C. Wainwright stuft Journey Medical mit "Kaufen" ein - Rosacea-Medikament Emrosi als entscheidender Faktor | 9 | Investing.com Deutsch | ||
| 25.08. | H.C. Wainwright initiates Journey Medical stock with Buy rating on Emrosi potential | 2 | Investing.com | ||
| 20.08. | Journey Medical setzt auf Rosacea-Mittel Imrozi für Profitabilitätswende | 5 | Investing.com Deutsch | ||
| 13.08. | Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples | 4 | Seeking Alpha | ||
| 12.08. | Journey Medical Corp - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 12.08. | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 553 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen | |
| 12.08. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 11.08. | Examining the Future: Journey Medical's Earnings Outlook | 2 | Benzinga.com | ||
| 07.08. | Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 | 3 | GlobeNewswire (USA) |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,755 | +0,07 % | Pfizer-Aktie: Konzern kämpft gegen Kursdruck | Pfizer ist die aktuell vielleicht interessanteste Dividenden-Aktie im Pharmasektor. Während Shortseller den Titel immer wieder unter Druck setzen, deuten operative Fortschritte und neue strategische... ► Artikel lesen | |
| GILEAD SCIENCES | 110,16 | +0,09 % | SA analyst upgrades/downgrades: GILD, UBER, FROG, JACK | ||
| ELI LILLY | 924,90 | +0,48 % | Ausschreibung Quality of Life Preis 2025: Lilly Deutschland Stiftung zeichnet Forschung zur gesundheitsbezogenen Lebensqualität aus | Bad Homburg (ots) - Die Lilly Deutschland Stiftung ruft Wissenschaftler:innen in der Lebensqualitätsforschung dazu auf, sich für den Quality of Life Preis 2025 zu bewerben. Die Bewerbungsfrist endet... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 372,30 | +0,45 % | VERTEX PHARMACEUTICALS INC stürzt ab - Alarmstufe Rot! | ||
| EYEPOINT PHARMACEUTICALS | 11,815 | -0,51 % | EyePoint Pharmaceuticals, Inc.: EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration | - No changes in protocol recommended for LUGANO and LUCIA clinical trials - - Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU - - On track... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 10,800 | -0,92 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 175,00 | +1,16 % | Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year | ||
| OPKO HEALTH | 1,143 | -0,63 % | JPMorgan initiates Opko Health stock with Neutral rating | ||
| JAZZ PHARMACEUTICALS | 156,40 | +1,82 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference | DUBLIN, Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company... ► Artikel lesen | |
| UNITED THERAPEUTICS | 412,70 | +0,15 % | United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base | ||
| ROYALTY PHARMA | 33,740 | -0,18 % | Dividendenbekanntmachungen (14.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,73 USD 0,6273 EUR AGCO CORPORATION US0010841023 0,29 USD 0,2492 EUR ALBEMARLE CORPORATION PREF A US0126532003 0... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,260 | +0,25 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500 | ||
| BRIDGEBIO PHARMA | 60,02 | +1,56 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
| TG THERAPEUTICS | 27,990 | +0,88 % | TG Therapeutics, Inc.: TG Therapeutics Makes 2025 Deloitte Technology Fast 500 List of America's Fastest-Growing Companies | ||
| AVADEL PHARMACEUTICALS | 19,900 | -0,50 % | Zürcher Kantonalbank: Avadel Pharmaceuticals plc | DJ Zürcher Kantonalbank: Avadel Pharmaceuticals plc
Zürcher Kantonalbank (AVDL)
Zürcher Kantonalbank: Avadel Pharmaceuticals plc
19-Nov-2025 / 16:15 CET/CEST
=----------------------------------------------------------------------------------------------------------------------... ► Artikel lesen |
JOURNEY MEDICAL CORPORATION gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 7,430 Euro und damit -1,46 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.